We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 502

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • June 19 2014

"Personalized medicine," in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs and preferences

USPTO issues new subject matter guidance post-Myriad and Prometheus

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • March 7 2014

The United States Patent and Trademark Office (USPTO) issued a new guidance document for Examiners on March 4, 2014, effective immediately

Permanent injunction granted despite patentee not having a product that practiced the claims of the patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 18 2014

On May 22, 2014, the Federal Court of Canada issued an injunction curtailing Janssen Inc.’s marketing of its drug ustekinumab (STELARA) in ongoing

Canadian patent term extension is coming

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian

Final injunction permits existing patients to continue to receive infringing medicine

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision

New guideposts for the fact-intensive hypothetical world of generic damages claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 14 2014

The past year has seen significant evolution in the Canadian law of generic pharmaceutical damages claims under section 8 of the Patented Medicines

Federal court dismisses notion that patents should be given only one interpretation for all purposes

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • June 19 2014

In a pair of simultaneously released decisions on June 13, 2014, Justice O'Reilly allowed Allergan's applications (the "Applications") prohibiting

Generic drug company licensees avoid patented medicines price oversight

  • Osler Hoskin & Harcourt LLP
  • -
  • Canada
  • -
  • June 10 2014

In nearly identical decisions released on May 27, 2014, Sandoz Canada Inc v Canada, 2014 FC 501 (Sandoz) and ratiopharm Inc v Canada, 2014 FC 502

PM(NOC) proceedings: Apotex defeats Bayer’s Canadian patent on oral contraceptive YAZ

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • June 19 2014

On June 4, 2014 Justice Roger Hughes of the Federal Court released his public reasons for dismissing Bayer's prohibition application against Apotex